Current Problems in Cancer
Volume 30, Issue 5 , Pages 203-232 , September 2006

A Review and an Update on the Screening of Epithelial Ovarian Cancer

  • Evelyn A. Reynolds, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Evelyn A. Reynolds, MD, Room 4307, Woodruff Research Building, Emory University, 1639 Pierce Drive, Atlanta, GA 30322
    • ,
  • Karen A. Moller, MD

References 

  1. American Cancer Society. Cancer Facts and Figures 2006. Available from: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
  2. National Cancer Institute. Cancer Stat Fact Sheets: Cancer of the Ovary. Available from: http://seer.cancer.gov/csr/1975_2003/results_merged/sect_21_ovary.pdf
  3. Berek JS . Epithelial ovarian cancer . In:  Berek JS ,  Hacker NF editor. Practical Gynecologic Oncology . Third Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 457–522
  4. Goff BA , Mandel L , Muntz HG , Melancon CH . Ovarian carcinoma diagnosis: Results of a national ovarian cancer survey . Cancer . 2000;89:2068–2075
  5. Prat J , Ribe A , Gallardo A . Hereditary ovarian cancer . Hum Pathol . 2005;36:861–870
  6. Bandera CA . Advances in the understanding of risk factors for ovarian cancer . J Reprod Med . 2005;50(6):399–406
  7. La Vecchia C . Epidemiology of ovarian cancer: a summary review . Eur J Cancer Prev . 2001;10:125–129
  8. Zografos GC , Panou M , Panou N . Common risk factors of breast and ovarian cancer: recent review . Int J Gynecol Cancer . 2004;14:721–740
  9. Modugno F . Ovarian cancer and high-risk women: implications for prevention, screening, and early detection . Gynecol Oncol . 2003;91:15–31
  10. Holschneider CH , Berek JS . Ovarian cancer: epidemiology, biology, and prognostic factors . Semin Surg Oncol . 2000;19:3–10
  11. Franceschi S , Parazzini F , Negri E . Pooled anyalysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use . Int J Cancer . 1991;49:61–65
  12. Rodriguez C , Patel AV , Calle EE , Jacob EJ . Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women . J Am Med Assoc . 2000;285:1460–1465
  13. Ness RB , Cramer DW , Goodman MT , Kjaer SK , Mallin K , Mosgaard BJ , et al.   Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies . Am J Epidemiol . 2002;155:217–224
  14. Risch HA . Hormonal etiology of epithelial ovarian cancer, with hypothesis concerning the role of androgens and progesterone . J Natl Cancer Inst . 1998;90:1774–1786
  15. Helzlsouer KJ , Alberg AJ , Gordon GB , Longcope C , Bush TL , Hoffman SC , et al.   Serum gonadotropins and steroid hormones and the development of ovarian cancer . J Am Med Assoc . 1995;274:1926–1930
  16. Whysner J , Mohan M . Perineal application of talc and cornstarch powders: evaluation of ovarian cancer risk . Am J Obstet Gynecol . 2000;182:720–724
  17. Strong K , Wald N , Miller A , Alwan A . Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group report on methodology of noncommunicable disease screening . J Med Screen . 2005;12:12–19
  18. ACOG Committee on Gynecologic Practice . The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer (ACOG Committee Opinion No. 280) . Obstet Gynecol . 2002;100:1413–1416
  19. U S . Preventive Services Task Force (Screening for ovarian cancer: recommendation statement) . Am Fam Physician . 2005;71(4):759–762
  20. Bast RC , Feeney M , Lazarus H , Nadler LM . Reactivity of a monoclonal antibody with human ovarian carcinoma . J Clin Invest . 1981;68:1331–1337
  21. Verheijen RHM , von Mensdorff-Pouilly S , van Kamp GJ , Kenemans P . CA125: fundamental and clinical aspects . Semin Cancer Biol . 1999;9:117–124
  22. Whitehouse C , Solomon E . Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening . Gynecol Oncol . 2003;88:S152–S157
  23. Menon U , Skates SJ , Lewis S , Rosenthal AN , Rufford B , Sibley K , et al.   Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer . J Clin Oncol . 2005;23(31):7919–7926
  24. United Kingdom Collaborative Trial of Ovarian Cancer Screening. Available from: http://www.ukctocs.org.uk/fact.htm
  25. Jacobs I , Davies AP , Bridges J , Stabile I , Fay T , Lower A , et al.   Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography . Br Med J . 1993;306(6884):1030–1034
  26. Jacobs IJ , Skates SJ , MacDonald N , Menon U , Rosenthal A , Davies AP , et al.   Screening for ovarian cancer: a pilot randomized controlled trial . Lancet . 1999;353:1207–1210
  27. Menon U , Skates SJ , Lewis S , Rosenthal AN , Rufford B , Sibley K , et al.   Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer . J Clin Oncol . 2005;23:7919–7926
  28. Buys SS , Partridge E , Greene MH , Prorok PC , Reding D , Riley TL , et al.   Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial . Am J Obstet Gynecol . 2005;193:1630–1639
  29. Olivier RI , Lubsen-Brandsma MAC , Verhoef S , van Buerden M . CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer . Gynecol Oncol . 2006;100:20–26
  30. Cohen LS , Escobar PF , Scharm C , Glimco B , Fishman DA . Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction . Gynecol Oncol . 2001;82:40–48
  31. Guerriero S , Ajossa S , Risalvato A , Lai MP , Mais V , Angiolucci M , et al.   Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses . Ultrasound Obstet Gynecol . 1998;11:277–282
  32. Guerriero S , Ajossa S , Melis GB . Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler? . Gynecol Oncol . 2002;84:352–353
  33. Bast RC , Badgwell D , Lu Z , Marquez R , Rosen D , Liu J , et al.   New tumor markers: CA125 and beyond . Int J Gynecol Cancer . 2005;15(S3):S274–S281
  34. Posadas EM , Davidson B , Kohn EC . Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature . Curr Opin Oncol . 2004;16:478–484
  35. Rapkiewicz AV , Espina V , Petricoin EF , Liotta LA . Biomarkers of ovarian tumours . Eur J Cancer . 2004;40:2604–2612
  36. Stevens EV , Liotta LA , Kohn EC . Proteomic analysis for early detection of ovarian cancer: a realistic approach? . Int J Gynecol Cancer . 2003;13(suppl 2):S133–S139
  37. Petricoin EF , Ardekani AM , Hitt BA , Levine PJ , Fusaro VA , Steinberg SM , et al.   Use of proteomic patterns in serum to identify ovarian cancer . Lancet . 2002;359:572–577
  38. Kong F , White CN , Xiao X , Feng Y , Xu C , He D , et al.   Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer . Gynecol Oncol . 2006;100:247–253
  39. Zhang Z , Bast RC , Yu Y , Sokoll LJ , Rai AJ . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer . Cancer Res . 2004;64:5882–5890
  40. Klug TL , Sattler MA , Colcher D , Schlom J . Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA71) on a novel pancarcinoma antigen (TAG72) . Int J Cancer . 1986;38:661–669
  41. Fayed ST , Ahmad SM , Kassim SK , Khalifa A . The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer . Disease Markers . 1998;14:155–160
  42. Hasholzner U , Baumgrtner L , Steiber P , Meier W , Reiter W , Pahl H , et al.   Clinical signficiance of the tumor markers CA125 II and CA72-4 in ovarian carcinoma . Int J Cancer . 1996;69:329–334
  43. Woolas RP , Conaway MR , Xu F , Jacobs IJ , Yu Y , Daly L , et al.   Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses . Gynecol Oncol . 1995;59:111–116
  44. Schutter EMJ , Sohn C , Kristen P , Mobus V , Crombach G , Kaufmann M , et al.   Estimation of the probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA125, and serum CA72-4 in postmenopausal women with a pelvic mass: an international multicenter study . Gynecol Oncol . 1998;69:56–63
  45. Kim J-H , Skates SJ , Uede T , Wong K-k , Schorge JO , Feltmate C , et al.   Osteopontin as a potential diagnostic biomarker for ovarian cancer . J Am Med Assoc . 2002;287(13):1671–1679
  46. Rosen DG , Wang L , Atkinson JN , Yu Y , Lu KH , Diamandis EP , et al.   Potential markers that complement expression of CA125 in epithelial ovarian cancer . Gynecol Oncol . 2005;99:267–277
  47. Brakora KA , Lee H , Yusuf R , Sullivan L , Harris A , Colella T , et al.   Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer . Gynecol Oncol . 2004;93:361–365
  48. Schorge JO , Drake RD , Lee H , Skates SJ , Rajanbabu R , Miller DS , et al.   Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer . Clin Cancer Res . 2004;10:3474–3478
  49. van Haaften-Day C , Shen Y , Xu F , Yu Y , Berchuck A , Havrilesky LJ , et al.   OVX1, macrophage-colony stimulating factor, and CA125II as tumor markers for epithelial ovarian carcinoma . Cancer . 2001;92(11):2837–2844
  50. Xu F-J , Ramakrishnan S , Daly L , Soper JT , Berchuck A , Clarke-Pearson D , et al.   Increased serum levels of macrophage colony-stimulating factor in ovarian cancer . Am J Obstet Gynecol . 1991;165: 1365–2
  51. Gadducci A , Ferdeghini M , Castellani C , Annicchiarico C , Prontera C , Facchini V , et al.   Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer . Gynecol Oncol . 1998;70:111–114
  52. Woolas RP , Xu F-J , Jacobs IJ , Yu Y-H , Daly L , Berchuck A , et al.   Elevation of multiple serum markers in patients with stage I ovarian cancer . J Natl Cancer Inst . 1993;85:1748–1751
  53. Xu Y , Shen Z , Wiper DW , Wu M , Morton RE , Elson P , et al.   Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers . J Am Med Assoc . 1998;280(8):719–723
  54. Sutphen R , Xu Y , Wilbanks GD , Fiorica J , Grendys EC , LaPolla JP , et al.   Lysophopholipids are potential biomarkers of ovarian cancer . Cancer Epidemiol Biomarkers Prev . 2004;13(7):1185–1191
  55. McIntosh MW , Drescher C , Karlan B , Scholler N , Urban N , Hellstrom KE , et al.   Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma . Gynecol Oncol . 2004;95:9–15
  56. Drapkin R , von Horsten HH , Lin Y , Mok SC , Crum CP , Welch WR , et al.   Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas . Cancer Res . 2005;65(6):2162–2169
  57. Hellstrom I , Raycraft J , Hayden-Ledbetter M , Ledbetter JA , Schummer M , McIntosh M , et al.   The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma . Cancer Res . 2003;63:3695–3700
  58. Rosen DG , Wang L , Atkinson JN , Yu Y , Lu KH , Diamandis EP , et al.   Potential markers that complement expression of CA125 in epithelial ovarian cancer . Gynecol Oncol . 2005;99:267–277

PII: S0147-0272(06)00033-X

doi: 10.1016/j.currproblcancer.2006.06.001

Current Problems in Cancer
Volume 30, Issue 5 , Pages 203-232 , September 2006

Article Tools

* Image Usage & Resolution